Details of the Drug

General Information of Drug (ID: DM0K4WQ)

Drug Name
PF-07261271
Indication
Disease Entry ICD 11 Status REF
Inflammatory bowel disease DD72 Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
DMA7E5

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-12 beta (IL12B) TTGW72V IL12B_HUMAN Not Available [2]
Vascular endothelial cell growth inhibitor (TNFSF15) TTEST6I TNF15_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Inflammatory bowel disease
ICD Disease Classification DD72
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-12 beta (IL12B) DTT IL12B 1.08E-01 0.13 0.17
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05536440) A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO CONTROLLED, DOSE ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE INTRAVENOUS AND MULTIPLE SUBCUTANEOUS AND INTRAVENOUS DOSES OF PF-07261271 IN HEALTHY PARTICIPANTS. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Pfizer